Product logins

Find logins to all Clarivate products below.


What is the opportunity for pharma during the treatment decision-making process? Cybercitizen Health U.S. 2015 Strategic Insight Report

With today’s consumers taking more responsibility for their healthcare decision-making than ever before, pharma must provide educational resources and decision support tools that help consumers parse their treatment options. What is the opportunity for pharma at this critical point in the patient journey? This Strategic Insight covers the essentials.

Question answered in this report:
What is the opportunity for pharma during the treatment decision-making process?

Related Multichannel Engagement Reports

Report
Patient Omnichannel Insights | Cybercitizen Health | 2023 | US | Pneumococcal Vaccines
Patient Omnichannel Insights | Cybercitizen Health | 2023 | US | Pneumococcal Vaccines Our 2023 study among patients and caregivers provides detailed insights and recommendations on the…
Report
Patient Omnichannel Insights | Cybercitizen Health | 2023 | US | HPV Vaccines
Patient Omnichannel Insights | Cybercitizen Health | 2023 | US | HPV Vaccines Our 2023 study among patients and caregivers provides detailed insights and recommendations on the information-…
Report
Patient Multichannel Insights | 2022 | Cybercitizen Health | Colombia | Segmentation
Patient Multichannel Insights | 2022 | Cybercitizen Health | Colombia (Segmentation Data Tables)
Report
Patient Multichannel Insights | 2022 | Cybercitizen Health | US | Multiple Myeloma | Segmentation
Patient Multichannel Insights | 2022 | Cybercitizen Health | US | Multiple Myeloma (Segmentation Data Deck)
Report
Patient Multichannel Insights | 2022 | Cybercitizen Health | US | AML VS CLL VS MM | Segmentation Data
Patient Multichannel Insights | 2022 | Cybercitizen Health | US | AML VS CLL VS MM (Segmentation Data Comparison Table)